Custom Search


Tuesday 13 September 2005

Yale Study Reconciles Two Models Of Schizophrenia

By: Yale University

Yale School of Medicine researchers published areport this month in the Archives of General Psychiatry that highlightsthe interplay of two brain signaling systems, glutamate and dopamine,in psychosis and cognitive function.

The study helps resolve a long-standing research debate between the"dopamine hypothesis" and the "glutamate hypothesis" or "PCP Model,"said John Krystal, M.D., professor, deputy chair for research in theDepartment of Psychiatry, and lead author of the study. "Both systemsappear to be involved," he said.

The first theory suggests that dopamine neurons are hyperactive inpersons with schizophrenia and that effects of the dopamine-releasingdrug, amphetamine, can mimic aspects of the illness. The second theorymaintains that certain schizophrenia-related deficits in the functionof glutamate, the dominant stimulatory transmitter, could be reproducedin healthy people by the administration of drugs such as ketamine,which block the NMDA subtype of glutamate receptors.

The study included 41 healthy subjects who were given amphetamine,ketamine and then saline, in varying sequence. The researchers foundthe transient psychotic state produced by each drug was similar but notidentical and that ketamine produced a more "complete"schizophrenia-like state than amphetamine. They also found thatcognitive impairments produced by ketamine, specifically workingmemory, were reduced by the administration of amphetamine.

"This study lends support to the hypothesis that drugs that facilitatethe function of particular dopamine receptors might play a role intreating cognitive impairments associated with schizophrenia," Krystal said.

Read Original Text

Use of this site is subject to the following terms of use